If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-08. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
== Medical uses == Ertugliflozin is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications or in addition to other medicinal products for the treatment of diabetes. A systematic review and meta-analysis of ertugliflozin, published in 2024, found it to have a good glycemic efficacy and a reassuring safety profile in managing type 2 diabetes.
Illarionov suggested that the plan of the General Staff apparently implied the escalation of the tensions and the South Ossetian units would have the role of the provocateurs in the first days of the hostilities. In August 2012, several South Ossetian officials told Vzglyad that the war began on 1 August 2008. Former Minister of Defence Mart Laar wrote in August 2013 that Russia was thoroughly preparing for the war and Georgia was drawn unprepared in the conflict. Russia planned that Georgian forces would be compelled to attack in South Ossetia. Georgian military initially did not plan to attack Tskhinvali. Russo-Georgian war refuted the view that Russia would not attack its neighbouring countries. Laar concluded that if Georgians had not been defending their country themselves for several days, Georgian state would no longer exist and a new government would be established.
The Landspítali – The National University Hospital of Iceland (Icelandic: Landspítali – Háskólasjúkrahús) offers a wide range of clinical services in outpatient clinics, day patient units, inpatient wards, clinical laboratories and other divisions. Landspítalinn also operates the psychiatric hospital Kleppur.
Sources: en.wikipedia.org
Hamas is a prescribed terrorist group in the UK, Israel and many other countries. The film is subsequently removed from BBC iPlayer. Nigel Farage gives up ownership of Reform UK, the party he founded as a private limited company in 2018, and relinquishes his shares in the organisation. Nathan Gill, the former leader of Reform UK in Wales, is charged with offences relating to bribery and is scheduled to appear in court on Monday 24 February. 21 February – The Parliamentary Commissioner for Standards launches an investigation into former minister Andrew Gwynne over the alleged sending of offensive messages through a WhatsApp group. Scottish Labour leader Anas Sarwar says he will deliver the "biggest reform of the NHS in decades" if his party wins the 2026 Scottish Parliament election. Wales's Social Justice Secretary, Jane Hutt, who is the UK's longest serving minister after service in successive Welsh Governments since 1999, announces she will retire from the Senedd in 2026. Sinn Féin confirms it will boycott St Patrick's Day events at the White House over US President Donald Trump's stance on the Israel-Gaza conflict. 24 February – Suspended Labour MP Mike Amesbury is sentenced to ten weeks in prison after admitting to punching a man to the ground in his Cheshire constituency. Westminster's Strangers' Bar is scheduled to reopen following a safety review. The establishment will have CCTV and extra security guards, while bar staff will be trained to look out for any potential safety issues.
Each year, approximately one million deaths are due to complications of cirrhosis, making cirrhosis the 11th most common cause of death globally. Cirrhosis and chronic liver disease were the tenth leading cause of death for men and the twelfth for women in the United States in 2001, killing about 27,000 people each year. The cause of cirrhosis can vary; alcohol and non-alcoholic fatty liver disease are main causes in western and industrialized countries, whereas viral hepatitis is the predominant cause in low and middle-income countries. Cirrhosis is more common in men than in women. The cost of cirrhosis in terms of human suffering, hospital costs, and lost productivity is high. Globally, age-standardized disability-adjusted life year (DALY) rates have decreased from 1990 to 2017, with the values going from 656.4 years per 100,000 people to 510.7 years per 100,000 people. In males DALY rates have decreased from 903.1 years per 100,000 population in 1990, to 719.3 years per 100,000 population in 2017; in females the DALY rates have decreased from 415.5 years per 100,000 population in 1990, to 307.6 years per 100,000 population in 2017. However, globally the total number of DALYs has increased by 10.9 million from 1990 to 2017, reaching the value of 41.4 million DALYs.
== Biosynthesis and occurrence == It is produced in eukaryotic organisms from succinate in complex 2 of the electron transport chain via the enzyme succinate dehydrogenase. Fumaric acid is found in fumitory (Fumaria officinalis), bolete mushrooms (specifically Boletus fomentarius var. pseudo-igniarius), lichen, and Iceland moss. Fumarate is an intermediate in the citric acid cycle used by cells to produce energy in the form of adenosine triphosphate (ATP) from food. It is formed by the oxidation of succinate by the enzyme succinate dehydrogenase. Fumarate is then converted by the enzyme fumarase to malate. Human skin naturally produces fumaric acid when exposed to sunlight. Fumarate is also a product of the urea cycle. Click on genes, proteins and metabolites below to link to respective articles.
The Golden Dome is a planned multi-layer missile defense system for the United States, intended to detect and destroy ballistic, hypersonic, and cruise missiles before they launch or during their flight. On January 27, 2025, President Donald Trump signed an executive order directing the secretary of defense to submit a plan for the Iron Dome for America system, which was later renamed Golden Dome. It extends former programs such as Prompt Global Strike, the Proliferated Warfighter Space Architecture, and the Strategic Defense Initiative. The initial name alluded to Israel's short-range Iron Dome system, but the Golden Dome would encompass the entire Earth, more like the Strategic Defense Initiative proposed by President Ronald Reagan in 1983. The system would employ a constellation of thousands of satellites equipped with sensors and interceptors that would be the first U.S. space weapons in orbit. Data centers in space would provide automated command and control through a cross-domain artificial intelligence-enabled network. Interceptors would fly in rapid orbit just outside the atmosphere, with only a small fraction available at the right time and place to act on any given threat—a flaw that critics argue makes the concept less efficient than traditional regional missile defenses such as the Iron Dome. In 2019, Donald Trump said the satellites would also carry offensive weapons.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.